Showing 1861-1870 of 2192 results for "".
- Anti-CD20 Therapies Outperform Platform DMTs in Pediatric MShttps://practicalneurology.com/news/high-efficacy-anti-cd20-vs-platform-therapies-in-prepubertal-pediatric-ms/2483537/Anti-CD20 therapies were associated with superior outcomes compared with traditional platform disease-modifying treatments (DMTs) for children with prepubertal-onset multiple sclerosis (MS) according to study results presented at the 41st Congress of the European Committee for Treatment and Resea
- 2024 McDonald Criteria Revisions Published in The Lancet Neurologyhttps://practicalneurology.com/news/2024-mcdonald-criteria-revisions-published-in-the-lancet-neurology/2483516/The 2024 revisions to the McDonald criteria for the diagnosis of multiple sclerosis (MS) have been published in The Lancet Neurology in September 2025, marking the first major update since 2017. The criteria were updated to reflect significant changes in the field, including an evolving
- FDA Greenlights Phase 2a Trial of Intranasal Foralumab in Multiple System Atrophyhttps://practicalneurology.com/news/fda-greenlights-phase-2a-trial-of-intranasal-foralumab-in-multiple-system-atrophy/2476103/The Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application, permitting the evaluation of treatment with intranasal foralumab (Tiziana Life Sciences, New York, NY) for people with multiple system atrophy (MSA) in a phase 2a clinical trial (NCT06868628). MSA i
- Accelerated FDA Approval Granted to First Treatment Targeting H3 K27M-Mutant Diffuse Midline Gliomahttps://practicalneurology.com/news/fda-grants-accelerated-approval-to-first-treatment-targeting-h3-k27m-mutant-diffuse-midline-glioma/2476100/The Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults and children aged ≥1 year with diffuse midline glioma harboring the H3 K27M mutation with disease progression following prior therapy. M
- New Findings Related to Blarcamesine Treatment for People with Alzheimer Disease Presented at AAIC 2025https://practicalneurology.com/news/new-findings-related-to-blarcamesine-treatment-for-people-with-alzheimer-disease-presented-at-aaic-2025/2475931/According to an analysis of results from the phase 2b/3 ANAVEX2-73-AD-004 clinical trial (NCT04314934), treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) yielded greater clinical response for people with Alzheimer disease (AD) who carried the homozygous wild-type (WT) <
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Sunosi Significantly Reduced Excessive Daytime Sleepiness and Obstructive Sleep Apnea Symptoms in Real-World Studyhttps://practicalneurology.com/news/sunosi-significantly-reduced-excessive-daytime-sleepiness-and-obstructive-sleep-apnea-symptoms-in-real-world-study/2475070/The results of a real-world analysis presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) show that Sunosi (solriamfetol; Axsome Therapeutics, New York, NY) significantly reduced symptoms of excessive daytime sleepiness (EDS) in individuals with obstructive s
- FDA Authorizes First Prescription Digital Therapeutic for Preventing Episodic Migrainehttps://practicalneurology.com/news/fda-authorizes-first-prescription-digital-therapeutic-for-preventing-episodic-migraine/2474512/The Food and Drug Administration (FDA) has granted marketing authorization to CT-132, a prescription digital therapeutic developed by Click Therapeutics (New York, NY), for the preventive treatment of episodic migraine in adults. CT-132 is the first FDA-authorized prescription digital therapeutic
- FDA Approves Neonatal Fc Receptor Blocker Treatment for Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/fda-approves-neonatal-fc-receptor-blocker-treatment-for-individuals-with-generalized-myasthenia-gravis/2474395/The Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab; Johnson & Johnson, New Brunswick, NJ) for the treatment of individuals aged >12 years with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK)
- Neurostimulation Device for Drug-Resistant Focal Epilepsy Demonstrates Significant, Long-Term Reductions in Seizureshttps://practicalneurology.com/news/neurostimulation-device-for-drug-resistant-focal-epilepsy-demonstrates-significant-long-term-reductions-in-seizures/2474345/Three-year data from a post-approval study (PAS; NCT02403843) of the NeuroPace Responsive Neurostimulation (RNS) System (Mountain View, CA) demonstrated significant and sustained reductions in seizures in adults with drug-resistant focal epilepsy (DRE). The results of the PAS presented at the Ame